

Mouse Anti-CD79a [JCB117]: MC0319, MC0319RTU7

Intended Use: For Research Use Only

Description: CD79 consist of two proteins, CD79a (mb-1) and CD79b (B29). CD79a recognizes the Ig-alpha protein, and CD79b recognizes the Ig-beta protein of the B-cell antigen component of the B-lymphocyte antigen receptor. The expression of CD79 precedes immunoglobulin (Ig) gene, heavy-chain gene rearrangement and CD20 expression. In precursor B cells, the CD79 protein chains are already expressed in the cytoplasm (CyCD79). Surface expression of CD79 begins at the pro-B cell stage and persists throughout the B-cell differentiation, and continues presents on plasma cells. CD79a is an excellent marker for identification of normal and neoplastic B lymphocytes. This CD79a antibody has been validated by the 9th International Conference on Human Leukocyte Differentiation Antigens (HLDA9).

Specifications


Clone: JCB117
 Source: Mouse
 Isotype: IgG1k
 Localization: Membrane
 Formulation: Antibody in PBS pH7.4, containing BSA and ≤ 0.09% sodium azide (NaN3)
 Storage: Store at 2°- 8°C
 Applications: IHC, Flow Cyt., ICC/IF, WB
 Package:

Description	Catalog No.	Size
CD79a Concentrated	MC0319	1 ml
CD79a Prediluted	MC0319RTU7	7 ml

IHC Procedure*

Positive Control Tissue: Tonsil, B cell lymphoma, Daudi or Ramos cells
 Concentrated Dilution: 50-200
 Pretreatment: Tris pH9.0, 15 minutes using Pressure Cooker, or 30-60 minutes using water bath at 95°-99°C
 Incubation Time and Temp: 30-60 minutes @ RT
 Detection: Refer to the detection system manual

* Result should be confirmed by an established diagnostic procedure.



FFPE human tonsil stained with anti-CD79a using DAB

References:

1. Primary Central Nervous System T-Cell Lymphoma With Aberrant Expression of CD20 and CD79a: A Diagnostic Pitfall. Gupta N, et al. Int J Surg Pathol. Oct;25(7):599-603, 2017.
2. Nodal marginal zone lymphoma: mutation status analyses of CD79A, CD79B, and MYD88 reveal no specific recurrent lesions. Gurth M, et al. Leuk Lymphoma. Apr;58(4):979-981, 2017.
3. CD79A: a novel marker for B cell neoplasms in routinely processed tissue samples. Mason, D.Y., et al. Blood 86: 1453-1459, 1995.